该计划的目的是提供来自淋巴瘤和成像领域的学术和行业专家联盟的共识建议,以确保成像评估与卢加诺分类的一致应用。方法:共识是通过由PINTaD(治疗和诊断药物成像网络)赞助的一系列会议获得的,作为ProLoG(淋巴瘤组织中的PINTaDRespOnse标准)共识计划的一部分。结果:共识建议涵盖卢加诺分类的所有技术成像方面。关于所需的成像系列和扫描访问,阐明了PET/CT和诊断CT的一些技术注意事项。以及PET图像的采集和重建以及病变大小和背景活动的影响。就影像学和临床审查员的作用以及培训和监测提出了建议。最后,提供了影像学病例报告表的示例模板,以支持卢加诺分类的有效数据收集。结论:提出了共识建议,以全面解决最终用户在分类中遇到的不一致和歧义的技术和成像领域。此类指南应用于支持卢加诺2014年的标准化采购和评估。
The aim of this initiative was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for the consistent application of imaging assessment with the Lugano classification. Methods: Consensus was obtained through a series of meetings from July 2019 to October 2021 sponsored by the PINTaD (Pharma Imaging Network for Therapeutics and Diagnostics) as part of the ProLoG (PINTaD RespOnse criteria in Lymphoma wOrking Group) consensus initiative. Results: Consensus recommendations encompass all technical imaging aspects of the Lugano classification. Some technical considerations for PET/CT and diagnostic CT are clarified with regards to required imaging series and scan visits, as well as acquisition and reconstruction of PET images and influence of lesion size and background activity. Recommendations are given on the role of imaging and clinical reviewers as well as on training and monitoring. Finally, an example template of an imaging case report form is provided to support efficient collection of data with Lugano Classification. Conclusion: Consensus recommendations are made to comprehensively address technical and imaging areas of inconsistency and ambiguity in the classification encountered by end users. Such guidance should be used to support standardized acquisition and evaluation with the Lugano 2014.